166 related articles for article (PubMed ID: 35332847)
21. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.
Bentayeb H; Aitamer M; Petit B; Dubanet L; Elderwish S; Désaubry L; de Gramont A; Raymond E; Olivrie A; Abraham J; Jauberteau MO; Troutaud D
J Exp Clin Cancer Res; 2019 Nov; 38(1):450. PubMed ID: 31684984
[TBL] [Abstract][Full Text] [Related]
22. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
[TBL] [Abstract][Full Text] [Related]
23. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
[TBL] [Abstract][Full Text] [Related]
24. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
25. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.
Mai Y; Yu JJ; Bartholdy B; Xu-Monette ZY; Knapp EE; Yuan F; Chen H; Ding BB; Yao Z; Das B; Zou Y; Young KH; Parekh S; Ye BH
Blood; 2016 Dec; 128(24):2797-2807. PubMed ID: 27737889
[TBL] [Abstract][Full Text] [Related]
26. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
[TBL] [Abstract][Full Text] [Related]
27. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.
Pfeifer M; Grau M; Lenze D; Wenzel SS; Wolf A; Wollert-Wulf B; Dietze K; Nogai H; Storek B; Madle H; Dörken B; Janz M; Dirnhofer S; Lenz P; Hummel M; Tzankov A; Lenz G
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12420-5. PubMed ID: 23840064
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
[TBL] [Abstract][Full Text] [Related]
29. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
31. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
32. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
[No Abstract] [Full Text] [Related]
33. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A.
Pulvino M; Liang Y; Oleksyn D; DeRan M; Van Pelt E; Shapiro J; Sanz I; Chen L; Zhao J
Blood; 2012 Aug; 120(8):1668-77. PubMed ID: 22791293
[TBL] [Abstract][Full Text] [Related]
34. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
[TBL] [Abstract][Full Text] [Related]
36. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma.
Xu W; Berning P; Erdmann T; Grau M; Bettazová N; Zapukhlyak M; Frontzek F; Kosnopfel C; Lenz P; Grondine M; Willis B; Lynch JT; Klener P; Hailfinger S; Barry ST; Lenz G
Leukemia; 2023 Jan; 37(1):178-189. PubMed ID: 36352190
[TBL] [Abstract][Full Text] [Related]
37. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
[TBL] [Abstract][Full Text] [Related]
38. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
[TBL] [Abstract][Full Text] [Related]
39. Cell-Penetrating Peptide Conjugated Au Nanoclusters Selectively Suppress Refractory Lymphoma Cells
Lai J; Yao Y; Zhang Y; Liu Y; Lu C; Meng C; Xia D; Li Y; Cao K; Gao X; Yuan Q
Bioconjug Chem; 2023 Jan; 34(1):228-237. PubMed ID: 36521093
[TBL] [Abstract][Full Text] [Related]
40. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.
Ding BB; Yu JJ; Yu RY; Mendez LM; Shaknovich R; Zhang Y; Cattoretti G; Ye BH
Blood; 2008 Feb; 111(3):1515-23. PubMed ID: 17951530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
